2018 ACVIM Forum Research Abstract Program: Seattle, Washington, June 14 - 15, 2018

Thoracic radiographs were performed at the time of LAR diagnosis and 3 dogs had marked interstitial and alveolar perihilar infiltration (CHF group) while the remainder 3 dogs had no pulmonary abnormalities and also no prior history of decompensated heart failure (non-CHF group). Diabetes mellitus (DM) is a common endocrinopathy in dogs and its impact on the cardiovascular system is still unclear in this species. In human medicine, serum fructosamine concentration (SFC) use as a cardiovascular prognostic is growing. The aim of this study was to evaluate correlations among systolic blood pressure (SBP), SFC, and insulin dose in use by diabetic dogs. A cross-sectional study was designed including diabetic dogs under treatment with NPH insulin (mean dose 0.62 U ± 0.24 U/kg, range 0.25 to 1.2 U/kg) for a period of 2 to 60 months (25.6 ± 17.8 months). The patients were assessed by Doppler vascular method to verify SBP in agreement with ACVIM guidelines. SFC were measurement by a colorimetric assay. Eighteen diabetic dogs (10.6 ± 2.9; 10.8 ± 8.1 kg) and twelve healthy control dogs (10.4 ± 3.1 years; 13.0 ± 9.4 kg) paired by breed, sex and age were included. There was a significantly positive correlation between SBP and SFC in diabetic dogs (r = 0.54; P < 0.05) as well as in control dogs (r = 0.57; P < 0.01). Insulin dose and SBP correlation only approach significance (r = 0.41; P = 0.08). Also, there was no correlation between time of diagnosis and SBP (r = 0.17; P = 0.47). Our findings suggests that there is association between SFC and hypertension in dogs. This results emphasize the importance of the SBP monitoring in diabetic dogs, and suggests that insulin dose may be a more important factor than the time of diagnosis as a risk factor for hypertension in canine diabetic patients. Amiodarone is predominantly a class III anti-arrhythmic drug that also blocks sodium channels, and calcium channels, and beta2-adrenergic receptors. It is commonly used for the treatment of tachyarrhythmias, most notably ventricular tachyarrhythmias. As a lipophilic, iodinated benzofuran-derivative medication, amiodarone has unique pharmacological and structural properties that not only distinguish it from other anti-arrhythmics, but warrants careful surveillance of certain metabolic processes. Its composition can lead to the inhibition of 5 0deiodinase activity, resulting in a decrease in Triiodothyronine (T3) production. Amiodarone and its main metabolite, desethylamiodarone may also block T3 binding to its respective receptor. Amiodarone induced thyroid dysfunction has been documented in people. We aimed to determine if amiodarone alters thyroid function in dogs treated for significant tachyarrhythmia.